Biodexa Pharmaceuticals Statistics
Total Valuation
BDRX has a market cap or net worth of $2.15 million. The enterprise value is -$3.75 million.
Important Dates
The next estimated earnings date is Monday, April 21, 2025, before market open.
| Earnings Date | Apr 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BDRX has 580,839 shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 580,839 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 5.38% |
| Float | 328,336 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.74 |
| Forward PS | n/a |
| PB Ratio | 0.12 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.16 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -96.81 |
Financial Efficiency
Return on equity (ROE) is -97.23% and return on invested capital (ROIC) is -55.03%.
| Return on Equity (ROE) | -97.23% |
| Return on Assets (ROA) | -37.52% |
| Return on Invested Capital (ROIC) | -55.03% |
| Return on Capital Employed (ROCE) | -62.77% |
| Revenue Per Employee | $4,995 |
| Profits Per Employee | -$410,371 |
| Employee Count | 21 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -307,101 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.84% in the last 52 weeks. The beta is 1.50, so BDRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -90.84% |
| 50-Day Moving Average | 4.32 |
| 200-Day Moving Average | 12.31 |
| Relative Strength Index (RSI) | 38.75 |
| Average Volume (20 Days) | 1,243,611 |
Short Selling Information
| Short Interest | 3,244 |
| Short Previous Month | 6,531 |
| Short % of Shares Out | 0.56% |
| Short % of Float | 0.99% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, BDRX had revenue of $104,895 and -$8.62 million in losses. Loss per share was -$45.20.
| Revenue | 104,895 |
| Gross Profit | 183,250 |
| Operating Income | -8.32M |
| Pretax Income | -9.56M |
| Net Income | -8.62M |
| EBITDA | -8.14M |
| EBIT | -8.32M |
| Loss Per Share | -$45.20 |
Full Income StatementBalance Sheet
The company has $6.39 million in cash and $482,768 in debt, giving a net cash position of $5.91 million or $10.17 per share.
| Cash & Cash Equivalents | 6.39M |
| Total Debt | 482,768 |
| Net Cash | 5.91M |
| Net Cash Per Share | $10.17 |
| Equity (Book Value) | 11.03M |
| Book Value Per Share | 30.42 |
| Working Capital | 5.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.80 million and capital expenditures -$27,803, giving a free cash flow of -$9.82 million.
| Operating Cash Flow | -9.80M |
| Capital Expenditures | -27,803 |
| Free Cash Flow | -9.82M |
| FCF Per Share | -$16.91 |
Full Cash Flow StatementMargins
| Gross Margin | 174.70% |
| Operating Margin | -7,931.30% |
| Pretax Margin | -8,508.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |